Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.
The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.
On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS. 

Media Releases

Latest Company News


Nov 2016 10:29 AM
Innate Immunotherapeutics (ASX..
21 November 2016 - Innate Immunotherapeutics (ASX:IIL) CEO, Simon Wilkinson, presents at the ASX CEO Sessions in Sydney.

Contact Information